Lyell Immunopharma, Inc. Tax Withholding Paid on Stock Awards
Lyell Immunopharma, Inc. (LYEL) reported Tax Withholding Paid on Stock Awards of $0 for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-05-06
- Lyell Immunopharma, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2026-03-31 was $0.00.
- Lyell Immunopharma, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- Lyell Immunopharma, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- Lyell Immunopharma, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- Lyell Immunopharma, Inc. payment, tax withholding, share-based payment arrangement for fiscal 2025 was $1.00K, a 98.68% decline from fiscal 2024.
- Lyell Immunopharma, Inc. payment, tax withholding, share-based payment arrangement for fiscal 2024 was $76.00K, a 83.37% decline from fiscal 2023.
- Lyell Immunopharma, Inc. payment, tax withholding, share-based payment arrangement for fiscal 2023 was $457.00K, a 0.87% decline from fiscal 2022.
- Lyell Immunopharma, Inc. payment, tax withholding, share-based payment arrangement for fiscal 2022 was $461.00K.
| Period end | Payment, Tax Withholding, Share-based Payment Arrangement 3 month | Payment, Tax Withholding, Share-based Payment Arrangement 6 month | Payment, Tax Withholding, Share-based Payment Arrangement 9 month | Payment, Tax Withholding, Share-based Payment Arrangement 12 month |
|---|---|---|---|---|
| 2026-03-31 | $0.00 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | $1.00K 10-K · filed 2026-03-12 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | $0.00 derived: sum of 3 quarters · filed 2026-03-12 | $76.00K 10-K · filed 2026-03-12 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $76.00K 10-Q · filed 2024-11-07 | $199.00K derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $76.00K 10-Q · filed 2024-08-07 | $199.00K derived: sum of 3 quarters · filed 2026-03-12 | $414.00K derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-03-31 | $76.00K 10-Q · filed 2024-05-06 | $199.00K derived: sum of 2 quarters · filed 2026-03-12 | $414.00K derived: sum of 3 quarters · filed 2026-03-12 | $464.00K derived: sum of 4 quarters · filed 2026-03-12 |
| 2023-12-31 | $123.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $338.00K derived: sum of 2 quarters · filed 2026-03-12 | $388.00K derived: sum of 3 quarters · filed 2026-03-12 | $457.00K 10-K · filed 2026-03-12 |
| 2023-09-30 | $215.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $265.00K derived: sum of 2 quarters · filed 2024-11-07 | $334.00K 10-Q · filed 2024-11-07 | $428.00K derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-06-30 | $50.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $119.00K 10-Q · filed 2024-08-07 | $213.00K derived: sum of 3 quarters · filed 2025-03-11 | $580.00K derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-03-31 | $69.00K 10-Q · filed 2024-05-06 | $163.00K derived: sum of 2 quarters · filed 2025-03-11 | $530.00K derived: sum of 3 quarters · filed 2025-03-11 | $530.00K derived: sum of 4 quarters · filed 2025-03-11 |
| 2022-12-31 | $94.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $461.00K derived: sum of 2 quarters · filed 2025-03-11 | $461.00K derived: sum of 3 quarters · filed 2025-03-11 | $461.00K 10-K · filed 2025-03-11 |
| 2022-09-30 | $367.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $367.00K derived: sum of 2 quarters · filed 2023-11-07 | $367.00K 10-Q · filed 2023-11-07 | $367.00K derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $0.00 10-Q · filed 2023-08-08 | $0.00 derived: sum of 3 quarters · filed 2024-02-28 | |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-04 | $0.00 derived: sum of 2 quarters · filed 2024-02-28 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $0.00 10-K · filed 2024-02-28 | ||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-08 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |